儿童重症监护中的宽松血压目标:PRESSURE随机临床试验
这项多中心、非盲、实用性随机临床试验在3个国家23个PICU纳入1900例接受有创通气和血管活性药物治疗低血压的危重患儿,干预组(n=957)设定年龄第5百分位以上的宽松平均动脉压目标,对照组(n=943)由主治医师设定目标。主要终点为30天死亡与有创通气持续时间的复合结局,两组无显著差异(概率指数0.52,95%CI 0.49-0.54,P=0.23)。宽松目标使去甲肾上腺素当量总剂量中位数降低37.5%;7项次要终点中6项相似,存活者PICU住院时间中位数在宽松组更短(159 vs 166小时;概率指数0.53,95%CI 0.50-0.56);肾脏替代治疗接受率和不良事件无差异。作者结论认为宽松平均动脉压目标与常规治疗相比30天死亡和有创通气持续时间无显著差异。
要点
- 在23个PICU、3个国家、1900例接受有创通气和血管活性药物的低血压危重患儿中,宽松平均动脉压目标(年龄第5百分位以上)与常规治疗相比,30天死亡和有创通气持续时间复合结局无显著差异(概率指数0.52,95%CI 0.49-0.54,P=0.23)。
- 宽松平均动脉压目标使去甲肾上腺素当量总剂量中位数较常规治疗组降低37.5%。
- 存活者PICU住院时间中位数在宽松目标组更短(159 vs 166小时;概率指数0.53,95%CI 0.50-0.56),为7项次要终点中唯一有显著差异者。
- 肾脏替代治疗接受率和不良事件在两组间无差异。
- 血管活性药物治疗期间平均动脉压中位数:宽松目标组58(51-63)mm Hg,常规治疗组61(54-67)mm Hg。
适用人群与场景
- 3个国家23个PICU中接受有创通气并因低血压接受血管活性药物治疗的危重患儿;纳入年龄中位数4(0-10)岁,44.8%为女性。
诊断标准与关键阈值
- 干预组设定宽松平均动脉压目标为大于年龄第5百分位;对照组平均动脉压目标由主治医师设定。
处置流程与药物剂量
- 干预组采用大于年龄第5百分位的宽松平均动脉压目标,以期减少血管活性药物暴露;对照组按主治医师设定的平均动脉压目标常规治疗。
研究设计与关键结果
- 多中心、非盲、实用性随机临床试验,23个PICU、3个国家,2021年11月至2026年5月纳入,随访至2026年6月完成30天结局;随机1900例(干预组n=957,对照组n=943),主要终点分析纳入宽松目标组910例、常规治疗组904例。
- 主要终点(30天死亡与有创通气持续时间的复合结局)两组无显著差异:概率指数0.52(95%CI 0.49-0.54),P=0.23。
- 血管活性药物治疗期间平均动脉压中位数(IQR):宽松目标组58(51-63)mm Hg,常规治疗组61(54-67)mm Hg。
- 宽松平均动脉压目标使去甲肾上腺素当量总剂量中位数较常规治疗组降低37.5%。
- 7项次要终点中6项两组相似;存活者PICU住院时间中位数(IQR)宽松目标组159(79-286)小时 vs 常规治疗组166(92-319)小时,概率指数0.53(95%CI 0.50-0.56)。
- 肾脏替代治疗接受率和不良事件两组无差异。
证据类型、等级与局限
- 证据类型:多中心、非盲、实用性随机临床试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接受有创通气和血管活性药物治疗低血压的危重患儿,采用年龄第5百分位以上的宽松平均动脉压目标与常规治疗相比30天死亡和有创通气持续时间无显著差异;作者结论认为宽松平均动脉压目标未显著改善该复合结局。
- 宽松目标可使去甲肾上腺素当量总剂量中位数降低37.5%,且存活者PICU住院时间中位数更短(159 vs 166小时)。
- 肾脏替代治疗接受率和不良事件无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Vasoactive drugs are often given to critically ill children to treat hypotension. However, optimal mean arterial pressure (MAP) targets are unknown.
OBJECTIVE: To evaluate whether adopting a permissive MAP target, and thereby potentially reducing exposure to vasoactive drugs, improves outcomes in hypotensive critically ill children.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter, unblinded, pragmatic randomized clinical trial was conducted in 23 pediatric intensive care units (PICUs) in 3 countries. Critically ill children receiving invasive ventilation and vasoactive drugs for hypotension were enrolled between November 2021 and May 2026. Follow-up to the 30-day outcome was completed in June 2026.
INTERVENTIONS: Patients randomized to the intervention (n = 957) were assigned a permissive MAP target greater than the fifth percentile for age. Patients in the control group (n = 943) received usual care with MAP target set by the attending physician.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of mortality and duration of invasive ventilation at 30 days. Secondary outcomes included mortality at PICU discharge, time to cessation of invasive ventilation, receipt and duration of kidney replacement therapy in PICU at 30 days, and length of PICU and hospital stay.
RESULTS: Of 1900 randomized patients, 910 in the permissive MAP target group and 904 in the usual care group were included for analysis of the primary outcome. Participants had a median (IQR) age of 4 (0-10) years and 44.8% were female; baseline characteristics were similar between the groups. Median (IQR) MAP while receiving vasoactive drugs was 58 (51-63) mm Hg in the permissive MAP target group and 61 (54-67) mm Hg in the usual care group. A permissive MAP target led to a 37.5% reduction in median norepinephrine-equivalent total dose compared with the usual care group. There was no significant difference between the groups in the primary outcome (probabilistic index, 0.52 [95% CI, 0.49-0.54]; P = .23). Six of the 7 secondary outcomes were similar between the groups, except median (IQR) PICU length of stay was significantly shorter in survivors in the permissive MAP target vs usual care group (159 [79-286] vs 166 [92-319] hours); probabilistic index, 0.53 [95% CI, 0.50-0.56]). Receipt of kidney replacement therapy and adverse events did not differ between the groups.
CONCLUSIONS AND RELEVANCE: Adopting a permissive MAP target resulted in no significant difference in mortality and duration of invasive ventilation at 30 days compared with usual care.
TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN20609635; Swiss National Clinical Trial Portal: SNCTP000006590.
参考来源
- Inwald DP, Laing E, Broomhall JM, et al. Permissive Blood Pressure Targets in Pediatric Critical Care: The PRESSURE Randomized Clinical Trial. JAMA. 2026. PMID: 42806496. doi:10.1001/jama.2026.19747
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。